JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6–12 months...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Harada, Daijiro, Takigawa, Nagio, Ochi, Nobuaki, Ninomiya, Takashi, Yasugi, Masayuki, Kubo, Toshio, Takeda, Hiromasa, Ichihara, Eiki, Ohashi, Kadoaki, Takata, Saburo, Tanimoto, Mitsune, Kiura, Katsuyuki
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2012
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659254/
https://ncbi.nlm.nih.gov/pubmed/22712764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02363.x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki